搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
BioWorld
8 小时
Movano rings up FDA pulse ox clearance for Eviemed
Movano Inc., dba Movano Health, added some clinical-grade glitz to its Evie ring with a U.S. FDA clearance for the built-in pulse oximeter. Movan’s stock shot up from an all-time low within minutes of ...
BioWorld
9 小时
Phase II Huntington’s tie-up with Novartis could edge $3B for PTC
PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...
Managed Healthcare Executive
13 小时
Johnson and Johnson Submits FDA Request for Pediatric Tremfya Approval
If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...
1 天
11/23
11/23,FDA 批准 BridgeBio Pharma $BridgeBio Pharma(BBIO)$ 的 Attruby (acoramidis) 用于降低转甲状腺素蛋白淀粉样心肌病 (ATTR-CM) 患者的心血管死亡和心血管相关住院率,与辉瑞的 tafamidis 展开直接竞争,后者具有相同的作用机制,但批准的适应症更有限。 Attruby 是一种口服 TTR 稳定剂,FDA的批准称该 ...
The Pharma Letter
1 天
The week in pharma: action, reaction and insight – week to November 29
Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...
3 天
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
Opinion
5 天
Opinion
A Short Lesson in Drug Competition
See the new treatment that will break a Pfizer monopoly on a drug for heart disease.
BioPharma Dive
5 天
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC ...
BioSpace
5 天
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
6 天
Deutsche Bank Aktiengesellschaft Forecasts Strong Price Appreciation for Bath & Body Works ...
Bath & Body Works (NYSE:BBWI – Free Report) had its target price increased by Deutsche Bank Aktiengesellschaft from $51.00 to ...
ETF Daily News
6 天
BridgeBio Pharma (NASDAQ:BBIO) Receives FDA Approval for ATTR-CM Treatment ‘Attruby ...
The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈